

Optiscan^o

Half-year Report 31st Dec 2024

ABN 81 077 771 987



Optiscan^o

Optiscan Imaging Limited (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of imaging technologies for medical, translational and pre-clinical applications. Its technology enables real-time, non-destructive, 3D, in-vivo digital imaging at the single-cell level, and bridges the gap between surgery and pathology.



Contents

Corporate directory	3
Highlights	4
Directors' report	5
Half-year in review	6
Advancement of product development pipeline	8
Product development highlights	9
Operational highlights	12
Auditor's independence declaration	14
Consolidated statement of profit or loss and other comprehensive income	15
Consolidated statement of financial position	16
Consolidated statement of changes in equity	17
Consolidated statement of cash flows	18
Notes to the consolidated financial statements	19
Directors' declaration	23
Independent auditor's review report to the members of Optiscan Imaging Limited	24
References	26

Corporate directory

Directors

Mr Robert Cooke
Non-executive Chairman

Dr Camile Farah
Managing Director

Ms Karen Borg
Non-executive Director

Mr Ron Song
Non-executive Director

Mr Sean Gardiner
Non-executive Director

Company Secretary

Elissa Hansen

Registered office

16 Miles Street
Mulgrave, Victoria 3170
Phone No.: (03) 9538 3333

Principal place of business

16 Miles Street
Mulgrave, Victoria, 3170
Phone No.: (03) 9538 3333

Share register

Computershare Investor Registry Services
Yarra Falls
452 Johnson Street,
Abbotsford, Victoria, 3067
Phone No.: (03) 9415 5000

Auditor

William Buck
Level 20
181 William Street
Melbourne VIC 3000

Stock exchange listing

Optiscan Imaging Limited securities are listed on the Australian Securities Exchange (ASX code: OIL)

Website

www.optiscan.com

Highlights



Completed design, development and build of Optiscan's dedicated pathology device and revealed the InForm™



Commenced development of a dedicated veterinary imaging product



Successful Advance Overseas Finding Application with the Australian Government, resulting in an additional \$1m R&D tax refund



Sale of ViewnVivo® in China and increased business development activities in the US and Europe



Collaboration with University of Minnesota College of Veterinary Medicine to begin research for the veterinary market



Manufactured several InVue® imaging devices for testing and clinical studies to be done at the Royal Melbourne Hospital and Mayo Clinic

Directors' report

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity' or the 'Group') consisting of Optiscan Imaging Limited (referred to hereafter as 'Optiscan', the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31st December 2024.

Principal activities

The principal activity of the consolidated entity during the year was the development of a suite of hardware and software solutions for real-time digital pathology and precision surgery under its own label, a collaboration with Carl Zeiss Meditec, and developing new pre-clinical markets for Optiscan's ViewnVivo® products and services.

Directors

The following persons were directors of Optiscan Imaging Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:



Mr Robert Cooke
Non-executive Chairman



Dr Camile Farah
Managing Director



Ms Karen Borg
Non-executive Director



Mr Ron Song
Non-executive Director



Mr Sean Gardiner
Non-executive Director

Half-year in review

Financial Highlights



Financial performance

During the 6-month period to 31st December 2024 (H1FY25), the consolidated entity generated ordinary revenue of \$593,757 from sales, system rentals and the provision of services, compared to \$449,254 in the previous corresponding period. The 32% increase in sales was mainly due to higher sales from Carl Zeiss Meditec (CZM).

Other income generated for the financial year was \$2,394,516 (2024: \$608,755). The Company recorded research and development (R&D) incentive income for H1FY25 of \$1,824,716, an increase of \$1,469,804 from the previous corresponding period (2024: \$354,912), mainly due to the successful Advance and Overseas Finding that enables the Company to receive an R&D tax incentive on overseas R&D cost. With multiple R&D projects running in parallel, the increased R&D expense contributed to the R&D incentive income accrued for the half-year. Following the successful CRC-P grant announced in FY24, the Company has received \$361,907 for the half-year (H1FY25).

Total expenses for H1FY25, excluding research and development and intellectual property expenses were \$2,524,584, a decrease of \$73,888 from the corresponding period (2024: \$2,598,472). Research and development and intellectual property expenses were \$2,549,173, an increase of \$760,888 from the previous corresponding period of \$1,788,285. This higher investment in R&D has accelerated the progress of multiple applications of Optiscan's technology in areas such as precision surgery (InVue®), pathology, telepathology, gastrointestinal (GI), and veterinary.


Financial position

The net assets decreased by \$2,284,183 to \$11,583,308 at 31st December 2024 (30th June 2024: \$13,867,491) primarily due to cash used for R&D and operating activities. The working capital position of the consolidated entity as at 31st December 2024, resulted in an excess of current assets over current liabilities of \$11,304,070 (30th June 2024: \$13,311,323).

Net cash used in operating activities was \$3,764,923, an increase of \$116,709, compared to the corresponding period (2024: operating cash outflows of \$3,648,214). Overall, there was a net increase in cash and equivalents of \$1,175,432 for the half-year (H1FY25) due to the maturity of term deposits that resulted in net cash generated from investing activities of \$5,129,477.

Unlocking Optiscan's potential: A strategic vision for the future


Over the past three years, Optiscan has undergone a strategic transformation. This has resulted in a more strategically focused company that plans future growth on an expanding product portfolio, built on the foundation of our core patented technology. Our core technology, a miniaturised high-resolution endomicroscope (which reveals subcellular detail), has potential applications in clinical, life sciences, and veterinary settings. By working closely with consultants and experts in various fields, we have gathered market research evidence supporting entry into multiple markets, with their respective market sizes* indicated below.



*Market sizes depicted in this pie chart are not to scale and are intended for representational purposes only.

All figures in the chart are represented in \$ (US) and their reference sources are listed at the end of this report under 'References'.

Advancement of product development pipeline




Product development highlights

Application

Focus Areas

Progress

Veterinary



- Aim towards completing the design and development of the veterinary imaging device with the planned unveiling in early FY26.
- Evaluate and finalise regulatory pathways strategy in preparation for submission to the FDA in FY26.
- Progress collaboration with University of Minnesota to explore clinical applications of Optiscan's technology in the veterinary market.

- Strategic decision to expand into the veterinary market, which has significant growth opportunity, with the U.S. market alone valued at approximately USD \$11.92 billion in 2022 and projected to grow at a CAGR of 8.7% through 2030.
- Memorandum of Understanding (MOU) and Collaborative Research Agreement signed with University of Minnesota College of Veterinary Medicine, aimed at assisting Optiscan's expansion into the veterinary market. The collaboration will explore clinical applications of confocal imaging technology in companion animals, particularly in cancer diagnostics, and supports the development of innovative veterinary imaging solutions.
- Commenced the design and development of a dedicated veterinary imaging device tailored to the specific needs of the veterinary market.
- Advanced go-to market strategy collaborating with key veterinary sector experts in developing and validating the company's plan.

Surgical - InVue®



- Advance FDA pre-submission in Q3 FY25, followed by a formal meeting with the FDA on regulatory pathways.
- Initiate and progress the Breast Cancer Study at the Royal Melbourne Hospital (RMH) following the ethical clearance received from the RMH Human Research Ethics Committee.
- Preparation for more extensive clinical studies to be conducted at the Mayo clinic, subject to FDA review and approvals.

- Following the reveal of InVue® in June 2024, substantial progress was made on the InVue® product development.
- Ethical clearance received from Royal Melbourne Hospital Human Research Ethics Committee for Breast Cancer Study utilising unveiled InVue® precision surgery imaging platform.
- Manufactured several InVue® imaging devices for testing and clinical studies to be done at the Royal Melbourne Hospital and Mayo Clinic.

Application

Focus Areas

Progress

Pathology - InForm™



- After successfully revealing InForm™, a medical imaging device that will transform pathology, more analysis will be conducted on the device with a current spatial resolution of 0.55 and offering up to 1000x real magnification at point of care, compared to the 40-100x magnification of conventional light microscopes.
- Evaluate regulatory pathways most appropriate to pursue.

- Successful reveal of InForm™ in February 2025, a next generation microscopic medical imaging device that is set to transform pathology by delivering real-time digital pathology insights across the full pathology workflow.
- Substantial enhancements were made to InForm™ prior to its revealing, including the application software specifically designed for use in pathology workflows.


Oral - InVivage®



- Advance FDA pre-submission, followed by a formal meeting with the FDA on regulatory pathways.

- Continued discussions with the FDA on regulatory pathways for Optiscan's InVivage® product.
- Progressed documentation and clinical planning processes, in preparation for FDA pre-submission.

AI/ML Applications



- Progress AI/ML development for use in various applications.

- Continued progress on annotating images for AI/ML applications.
- More progress will be made in AI/ML when clinical studies start to advance as it facilitates the vital step of collecting data that will be used for developing AI/ML models and algorithms.

Application

Focus Areas

Progress

Flexible GI



- Progress through the R&D work to develop an Edge-AI-enabled gastrointestinal flexible endomicroscope.

- Completion of the clinical endomicroscope prototype and delivered to University Medical Centre of the Johannes Gutenberg University Mainz, Germany for evaluation with renowned world-leading gastroenterologist Professor Ralph Kiesslich.
- Signed agreement with Monash University to collaborate on developing the CRC-P supported project next-gen AI technology.

Robotics



- Development of detailed design work with Mayo Clinic, that will lay the foundation for prototype development.

- Advanced collaboration with Mayo Clinic through an onsite visit by Optiscan's team at Mayo Clinic in Rochester, Minnesota. This collaboration provided valuable design inputs, identified user needs, and facilitated specific design refinements for confocal probes intended for robotic surgical systems.
- Established processes around iterative testing and feedback cycles with Mayo Clinic surgeons, ensuring that the designs align seamlessly with real-world surgical workflows.

Telepathology



- Completion of the Minimum Viable Product (MVP) phase of Optiscan's cloud-based telepathology platform by Q3 FY25.

- Advanced the Minimum Viable Product (MVP) phase of Optiscan's cloud-based telepathology platform by integrating robust features such as remote session management and automated report generation.
- Updated clinical devices to ensure seamless compatibility with the platform, facilitating efficient workflows for remote users.

Operational highlights

Sales pipeline develops from marketing strategy

Optiscan advanced its sales and marketing strategy during the first half of 2025 (H1FY25). This effort resulted in an expansion of the sales pipeline for its ViewnVivo® life-sciences device, particularly in the United States, driven by increased activities from the US-based business development team.

United States

As part of the business development strategy to engage more with potential customers and partners, the team in the US exhibited at four conferences across the United States and Canada over the last six months.

- World Molecular Imaging Congress 2024 at Montreal
- Cell Bio24 by American Society for Cell Biology at San Diego
- American College of Veterinary Surgeons (ACVS) Annual Surgery Summit at Phoenix
- American College of Veterinary Pathologists (ACVP) 2024 Annual Meeting at Seattle

Participation in conferences led to numerous new prospect interactions, revenue opportunities and additional market awareness within the life sciences, veterinary and pharmaceutical market segments. The experience gained by the team from the conference resulted in establishing a critical sales execution process within the US and Canadian markets to support further growth opportunities. Several quotes were issued for the sale of the ViewnVivo® to tier 1 research institutions, with additional leads expected to progress dependent on grant funding applications.

Optiscan's strategy to enter the veterinary market included participation at two conferences, ACVS and ACVP, which resulted in several business development outcomes. These events enabled discussions with potential collaborators and customers, and several business development opportunities are now being pursued in the veterinary research space. This approach establishes foundational relationships and prepares for adoption across various veterinary applications.

Europe

Optiscan's business development efforts in Europe have been fruitful, focusing on nurturing existing leads and expanding the sales pipeline with new opportunities. Discussions with leading oncology research institutions and in vivo imaging facilities have aligned with Optiscan's strategic goals in the pre-clinical research space, contributing to pipeline growth and long-term market presence.

China

Optiscan continued to work closely with our China-based distribution partners throughout the first half-year (H1 FY25). This resulted in an additional sale of the ViewnVivo® to a large Chinese university following success in a competitive tender process.

Other opportunities are being pursued in China which have several stages before the sales outcomes can be determined. During the half-year, two funding applications for purchases of the ViewnVivo® for pre-clinical research applications were submitted by two separate institutions in October 2024. The outcomes of the funding applications are expected in Q3 FY25 and Q1 FY26, and if successful, these funding applications will be followed by mandatory public tender processes, illustrating the long sales cycle for research capital equipment purchase decisions.

Optiscan also participated in Austrade's "From GBA to China" tour in Hong Kong and Shenzhen, which led to some new potential opportunities in the region. Overall, the market opportunity in China is big, and the team is continuing its strategy to penetrate the market.

Marketing, communications and public relations initiatives

With the Company's strategic transformation over the past three years, it was important to communicate clearly to the wider market the Company's strategic goals over the coming year and the long term. Optiscan's visibility and media presence continued to grow throughout the first half of FY25. Some notable ones were:

- **Investor roadshow in Sydney and Melbourne:** Meetings with retail and institutional investors, research analysts and capital markets to update on development strategy milestones and achievements.
- **Channel 7 News feature:** Highlighted the application of Optiscan's technology in revolutionizing the way cancer is detected and treated.
- **Mayo Clinic Beahrs Surgical Innovation Summit:** Dr. Farah participated as a panelist, engaging in discussions on transformative healthcare innovations at this invitation-only event.
- **Interview with Alan Kohler from Intelligent Investor:** Focused on Optiscan's role in advancing imaging solutions for cancer diagnostics.
- **Presentation at the Stocks on Track event:** Highlighted the Company's strategic roadmap and R&D progress.
- **Presentation at the ASX Gems Conference:** Provided insights into Optiscan's innovative technology and growth trajectory.
- **National Biotech and Commercialisation Summit:** Dr. Farah contributed to discussions which resulted in a joint communiqué and white paper aimed at advancing Australia's BioTech and MedTech sectors, with a particular focus on improving the development pipeline.

People and culture

Optiscan has strengthened its team by appointing a new Mechanical Engineer to support research and development as well as operational requirements. Additionally, Optiscan has secured external expertise in areas such as R&D, Regulatory Affairs, Project Management, and application-specific clinical and commercialisation fields. These strategic engagements have been crucial in advancing initiatives within the robotic surgery sector and the veterinary imaging market.

During the first half of FY25, Optiscan successfully achieved several significant milestones in compliance and operational efficiency. The company completed internal audits for ISO 13485:2016 standards and strengthened supplier relationships by signing quality agreements and an upgrade to an "A" grade supplier. Additionally, Optiscan made important procedural updates to document control, contamination control, and the quality manual, thereby enhancing adherence to regulatory requirements.

These outcomes and investments in human capital highlight Optiscan's dedication to developing a robust and highly skilled team. This positions the Company to accomplish its strategic objectives and provide innovative solutions across its target markets.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the consolidated entity during the financial half-year.

Matters subsequent to the end of the financial half-year

Optiscan has received its R&D Tax Incentive rebate for last year (FY24) amounting to \$1,775,733. This significantly higher amount compared to last year's (FY23) of \$672,320, is due to the successful application for an Advance and Overseas Finding that will enable the Company to claim R&D tax incentive on R&D cost incurred overseas. This additional cash received will be used to further invest in R&D activities that will lead to more innovative healthcare solutions to improve patient outcomes.

Elissa Hansen has been appointed Company Secretary of the Company as announced on 4th February 2025, replacing Justin Mouchacca.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report. This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors



Robert Cooke
Non-executive Chairman
27th February 2025

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the directors of Optiscan Imaging Limited

As lead auditor for the review of Optiscan Imaging Limited for the half-year ended 31 December 2024, I declare that, to the best of my knowledge and belief, there have been:

- no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- no contraventions of any applicable code of professional conduct in relation to the review.

This declaration is in respect of Optiscan Imaging Limited and the entities it controlled during the period.

William Buck

William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136

A. A. Finnis

A. A. Finnis
Director
Melbourne, 27 February 2025

Consolidated statement of profit or loss and other comprehensive income for the half-year ended 31st December 2024

	Note	31 Dec 2024 (\$)	31 Dec 2023 (\$)
Revenue	4	593,757	449,254
Cost of sales		(269,210)	(128,109)
Gross profit		324,547	321,145
Other income	5	2,394,516	608,755
Expenses			
Research & development and intellectual property expenses		(2,549,173)	(1,788,285)
Share-based payment expenses		(85,156)	(139,425)
Depreciation expense		(286,535)	(279,700)
Administration and general expenses		(2,146,177)	(2,168,778)
Finance costs		(6,715)	(10,569)
Loss before income tax expense		(2,354,693)	(3,456,857)
Income tax expense		(19,970)	-
Loss after income tax expense for the half-year attributable to the owners of Optiscan Imaging Limited		(2,374,663)	(3,456,857)
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		5,323	12,479
Other comprehensive income for the half-year, net of tax		5,323	12,479
Total comprehensive loss for the half-year attributable to the owners of Optiscan Imaging Limited		(2,369,340)	(3,444,378)

	Note	Cents	Cents
Basic loss per share	8	(0.28)	(0.43)
Diluted loss per share	8	(0.28)	(0.43)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Consolidated statement of financial position as at 31st December 2024

	Note	31 Dec 2024 (\$)	30 Jun 2024 (\$)
Assets			
Current assets			
Cash and cash equivalents		7,279,600	6,101,137
Trade and other receivables		2,970,871	1,567,792
Inventories		1,883,167	2,000,088
Term deposits		-	5,130,891
Other		550,665	265,979
Total current assets		12,684,303	15,065,887
Non-current assets			
Property, plant and equipment		220,299	259,727
Intangibles		5,747	156,792
Right-of-use assets		67,083	147,582
Total non-current assets		293,129	564,101
Total Assets		12,977,432	15,629,988
Liabilities			
Current liabilities			
Trade and other payables		664,042	1,040,409
Lease liabilities		78,348	180,601
Loans		122,696	40,304
Provisions		515,147	493,250
Total current liabilities		1,380,233	1,754,564
Non-current liabilities			
Lease liabilities		-	-
Provisions		13,891	7,933
Total non-current liabilities		13,891	7,933
Total liabilities		1,394,124	1,762,497
Net Assets		11,583,308	13,867,491
Equity			
Issued capital	6	88,525,039	88,525,039
Reserves		672,052	581,574
Accumulated losses		(77,613,783)	(75,239,122)
Total equity		11,583,308	13,867,491

The above statement of financial position should be read in conjunction with the accompanying notes

Consolidated statement of changes in equity for the half-year ended 31st December 2024

	Issued capital (\$)	Foreign currency translation reserve (\$)	Share based payments reserve (\$)	Accumulated losses (\$)	Total equity (\$)
Consolidated					
Balance at 1 July 2023	71,863,359	(4,435)	2,127,587	(70,942,074)	3,044,437
Loss after income tax expense for the half-year	-	-	-	(3,456,857)	(3,456,857)
Other comprehensive income for the half-year, net of tax	-	12,479	-	-	12,479
Total comprehensive income for the half-year	-	12,479	-	(3,456,857)	(3,444,378)
Transactions with owners in their capacity					
Contributions of equity, net of transaction costs	16,630,548	-	-	-	16,630,548
Share-based payments	-	-	139,425	-	139,425
Exercise of options	31,132	-	(7,132)	-	24,000
Lapsed options	-	-	(115,026)	115,026	-
Transfer of expired share based payments	-	-	(1,648,422)	1,648,422	-
Balance at 31 December 2023	88,525,039	8,044	496,432	(72,635,483)	16,394,032

	Issued capital (\$)	Foreign currency translation reserve (\$)	Share based payments reserve (\$)	Accumulated losses (\$)	Total equity (\$)
Consolidated					
Balance at 1 July 2024	88,525,039	(4,835)	586,408	(75,239,120)	13,867,492
Loss after income tax expense for the half-year	-	-	-	(2,374,663)	(2,374,663)
Other comprehensive income for the half-year, net of tax	-	5,323	-	-	5,323
Total comprehensive income for the half-year	-	5,323	-	(2,374,663)	(2,369,340)
Transactions with owners in their capacity as owners					
Share-based payments	-	-	85,156	-	85,156
Balance at 31 December 2024	88,525,039	488	671,564	(77,613,783)	11,583,308

The above statement of changes in equity should be read in conjunction with the accompanying notes

Consolidated statement of cash flows for the half-year ended 31st December 2024

	Note	31 Dec 2024	31 Dec 2023
		(\$)	(\$)
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		1,017,140	592,941
Payments to suppliers and employees (inclusive of GST)		(5,386,903)	(4,456,425)
Interest received		235,554	215,270
Receipt of research and development tax incentive		-	-
Receipt of government grants		398,098	-
Income taxes paid		(28,812)	-
Net cash used in operating activities		(3,764,923)	(3,648,214)
Cash flows from investing activities			
Payments for property, plant and equipment		(11,689)	(33,062)
Receipts/(Payments) for term deposits		5,141,166	(5,000,000)
Net cash generated from / (used in) investing activities		5,129,477	(5,033,062)
Cash flows from financing activities			
Proceeds from issue of shares		-	16,698,816
Proceeds from exercise of share options		-	24,000
Share issue transaction costs		-	(104,499)
Repayment of borrowings		(72,899)	(60,576)
Repayment of lease liabilities		(116,223)	(94,032)
Net cash generated from / (used in) financing activities		(189,122)	16,463,709
Net increase in cash and cash equivalents		1,175,432	7,782,433
Cash and cash equivalents at the beginning of the financial half-year		6,101,137	875,371
Effects of exchange rate changes on cash and cash equivalents		3,031	(6,702)
Cash and cash equivalents at the end of the financial half-year		7,279,600	8,651,102

The above statement of cash flows should be read in conjunction with the accompanying notes

Optiscan Imaging Limited

Notes to the financial statements

31st December 2024

Note 1. General information

The financial statements cover Optiscan Imaging Limited as a consolidated entity consisting of Optiscan Imaging Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Optiscan Imaging Limited's functional and presentation currency.

Optiscan Imaging Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

16 Miles Street, Mulgrave, Victoria, 3170

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 27th February 2025.

Note 2. Material accounting policy information

These general purpose financial statements for the interim half-year reporting period ended 31st December 2024 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30th June 2024 and any public announcements made by the Company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period.

The adoption of these new or amended Accounting Standards and Interpretations did not have an impact on the interim financial statements of the consolidated entity.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Note 3. Operating segments

Identification of reportable operating segments

The Company operated predominantly in the confocal endomicroscope industry within Australia. AASB 8 requires operating segments to be identified on the basis of internal reports about the components of the consolidated entity that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segment and to assess its performance. The board reviews the Company as a whole in the business segment of confocal endomicroscopes within Australia.

Optiscan Imaging Limited

Notes to the financial statements

31st December 2024

Note 4. Revenue

	31 Dec 2024	31 Dec 2023
	(\$)	(\$)
Sales revenue	593,757	449,254

Disaggregation of revenue

The disaggregation of revenue from contracts with customers is as follows:

Major product lines

Sale of goods (goods transferred at a point in time)	556,945	436,348
Services provided (services provided at a point in time)	36,812	12,906
	593,757	449,254

Geographical regions

Germany	309,003	169,535
China	191,143	266,813
Australia	56,800	12,906
United States	36,811	-
	593,757	449,254

Note 5. Other income

	31 Dec 2024	31 Dec 2023
	(\$)	(\$)
Government grants - R&D tax incentive*	1,824,716	354,912
Cooperative Research Centres - Projects (CRCP) grant	361,907	-
Interest income	202,020	267,778
Net foreign exchange gain/(loss)	5,873	(13,935)
Other income	2,394,516	608,755

*The Company was successful in its application for an Advance and Overseas Finding that will enable the Company to claim R&D tax incentive on R&D cost incurred overseas. As a result, the R&D tax incentive accrual for the half-year (H1FY25) has increased significantly to \$1,108,890. There was also an adjustment to last year's (FY24) claim for an additional \$715,826 relating to overseas R&D cost now claimable.

Optiscan Imaging Limited

Notes to the financial statements

31st December 2024

Note 6. Equity - issued capital

	31 Dec 2024	30 June 2024	31 Dec 2024	30 June 2024
	Shares	Shares	(\$)	(\$)
Ordinary shares - fully paid	835,340,803	835,340,803	88,525,039	88,525,039

Movements in issued capital

Details	Date	Shares	(\$)
Balance	1 Jul 2024	835,340,803	88,525,039
Balance	31 Dec 2024	835,340,803	88,525,039

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Note 7. Events after the reporting period

Optiscan has received its R&D Tax Incentive rebate for last year (FY24) amounting to \$1,775,733. This significantly higher amount compared to last year's (FY23) of \$672,320, is due to the successful application for an Advance and Overseas Finding that will enable the Company to claim R&D tax incentive on R&D cost incurred overseas. This additional cash received will be used to further invest in R&D activities that will lead to more innovative healthcare solutions to improve patient outcomes.

Elissa Hansen has been appointed Company Secretary of the Company as announced on 4th February 2025, replacing Justin Mouchacca.

Optiscan Imaging Limited

Notes to the financial statements

31st December 2024

Note 8. Earnings per share

	31 Dec 2024	31 Dec 2023
	(\$)	(\$)
Loss after income tax attributable to the owners of Optiscan Imaging Limited	(2,374,663)	(3,456,857)
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	835,340,803	810,674,860
Weighted average number of ordinary shares used in calculating diluted earnings per share	835,340,803	810,674,860
	Cents	Cents
Basic earnings per share	(0.28)	(0.43)
Diluted earnings per share	(0.28)	(0.43)

As at 31st December 2024, Optiscan has 13,100,000 unlisted options on issue. These options are considered to be non-dilutive as Optiscan incurred a loss for the reporting period.

Directors' declaration

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31st December 2024 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable;

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



Robert Cooke

Non-executive Chairman

27th February 2025

Independent auditor's review report to the members of Optiscan Imaging Limited

Report on the half-year financial report



Our conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Optiscan Imaging Limited (the Company), and its subsidiaries (the Group) does not comply with the *Corporations Act 2001*, including:

- giving a true and fair view of the Group's financial position as at 31 December 2024 and of its financial performance for the half-year then ended; and
- complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

What was reviewed?

We have reviewed the accompanying half-year financial report of the Group, which comprises:

- the consolidated statement of financial position as at 31 December 2024,
- the consolidated statement of profit or loss and other comprehensive income for the half-year then ended,
- the consolidated statement of changes in equity for the half-year then ended,
- the consolidated statement of cash flows for the half-year then ended,
- notes to the financial statements, including material accounting policy information, and
- the directors' declaration.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's responsibilities for the review of the financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Responsibilities of the directors for the financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2024 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

William Buck

William Buck Audit (Vic) Pty Ltd
ABN 59 116 151 136

Alan F...

A. A. Finnis
Director
Melbourne, 27 February 2025

References*

Clinical – Global healthcare spending - <https://www2.deloitte.com/content/dam/Deloitte/global/Documents/Finance/gx-rise-global-health-care.pdf>

Oral Cancer - <https://www.marketresearchfuture.com/reports/oral-cancer-treatment-market-1820>

Breast Cancer - <https://www.precedenceresearch.com/breast-cancer-market>

GI Market - <https://www.statista.com/outlook/hmo/hospitals/inpatient-care/gastroenterology/worldwide>

Clinical Pathology - <https://www.marketsandmarkets.com/Market-Reports/anatomic-pathology-market-137323145.html>

Veterinary Medicine - <https://www.grandviewresearch.com/industry-analysis/veterinary-medicine-market>

Veterinary Pathology - <https://www.grandviewresearch.com/industry-analysis/veterinary-diagnostics-market>

Veterinary Surgery - <https://www.marketsandmarkets.com/Market-Reports/veterinary-surgical-procedures-market-192772026.html>

Veterinary Oncology - <https://www.grandviewresearch.com/industry-analysis/veterinary-oncology-market>

Life Sciences - <https://www.grandviewresearch.com/industry-analysis/life-science-tools-market>

Global AI in Healthcare - <https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html>

Robotic Surgery - <https://www.grandviewresearch.com/industry-analysis/surgical-robot-market>

Telepathology - <https://www.futuremarketinsights.com/reports/digital-telepathology-market>

*The figures used taken from the reference sources listed were accurate when this report was released. Optiscan Imaging Limited does not take responsibility for the accuracy of the figures at any point in time.

Head office

Optiscan Imaging Limited
16 Miles Street,
Mulgrave, Victoria 3170
Australia

Contact info

+613 9538 3333
info@optiscan.com



Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacture and commercialisation of endomicroscopic digital imaging technology solutions for medical, translational and pre-clinical applications.

Our unique technology offers real-time, 3D, in vivo imaging at the single-cell level, in a non-destructive manner that enables clinicians to make immediate informed decisions.

We are driven by delivering digital healthcare solutions giving healthcare providers and researchers high quality, live, microscopic images and associated tools.

Our technology helps facilitate earlier detection and management of disease thus improving patient outcomes and reducing the cost of curative medicine and associated procedures within healthcare systems.

We are united in the common pursuit of revolutionising healthcare with live digital microscopic solutions that enable immediate informed decisions, provide economic efficiencies within health systems and improve patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on LinkedIn.